ArticleGeroScience2023
Plasma metabolomic signatures of dual decline in memory and gait in older adults.
Article in GeroScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Mitochondrial quality control in human ageing and longevity.Nature metabolism · 2026Review
- Characterization of the plasma proteomic profile of dual trajectories in cognitive status and physical performance.GeroScience · 2026Article
- Article
- Plasma lipids connecting olfaction with cognition and physical function.Scientific reports · 2026Article
- Data from multi-national aging cohorts show dysregulated metabolic pathways in people with physio-cognitive decline.Communications medicine · 2025Article
- Plasma proteomic signatures of dual cognitive and mobility decline in older adults.EBioMedicine · 2025Article
- Article
- Metabolomic Pathways of Inflammation and Mitochondrial Dysfunction Are Related to Worsening Healthy Aging Index and Mortality.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Ursodeoxycholic acid prompts glycolytic dominance, reductive stress and epithelial-to-mesenchymal transition in ovarian cancer cells through NRF2 activation.Cell death discovery · 2025Article
- Serum Proteomic and Metabolomic Signatures of High Versus Low Physical Function in Octogenarians.Aging cell · 2025Article
- Article
- Higher skeletal muscle mitochondrial oxidative capacity is associated with preserved brain structure up to over a decade.Nature communications · 2024Article
- Metabolite signatures of chronological age, aging, survival, and longevity.Cell reports · 2024Article
- Shared plasma metabolomic profiles of cognitive and mobility decline predict future dementia.GeroScience · 2024Article
- Article
- Presymptomatic Profiles of Cognitive Impairment with Prior Mobility Impairment.Journal of the American Medical Directors Association · 2024Article
- Advancing Personalized Medicine by Analytical Means: Selection of Three Metabolites That Allows Discrimination between Glaucoma, Diabetes, and Controls.Metabolites · 2024Article
- Circulating Neurofilament Light Chain Levels Increase with Age and Are Associated with Worse Physical Function and Body Composition in Men but Not in Women.International journal of molecular sciences · 2023Article
- Dual cognitive and mobility impairments and future dementia - Setting a research agenda.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Older adults experiencing dual decline in memory and gait have greater dementia risk than those with memory or gait decline only, but mechanisms are unknown. Dual decline may indicate specific pathophysiological pathways to dementia which can be reflected by circulating metabolites. We compared longitudinal changes in plasma metabolite biomarkers of older adults with and without dual decline in the Baltimore Longitudinal Study of Aging (BLSA). Participants were grouped into 4 phenotypes based on annual rates of decline in verbal memory and gait speed: no decline in memory or gait, memory decline only, gait decline only, and dual decline. Repeated measures of plasma metabolomics were measured by biocrates p500 kit during the same time of memory and gait assessments. In BLSA, 18 metabolites differed across groups (q-value < 0.05). Metabolites differentially abundant were enriched for lysophosphatidylcholines (lysoPC C18:0,C16:0,C17:0,C18:1,C18:2), ceramides (d18:2/24:0,d16:1/24:0,d16:1/23:0), and amino acids (glycine) classes. Compared to no decline, the dual decline group showed greater declines in lysoPC C18:0, homoarginine synthesis, and the metabolite module containing mostly triglycerides, and showed a greater increase in indoleamine 2,3-dioxygenase (IDO) activity. Metabolites distinguishing dual decline and no decline groups were implicated in metabolic pathways of the aminoacyl-tRNA biosynthesis, valine, leucine and isoleucine biosynthesis, histidine metabolism, and sphingolipid metabolism. Older adults with dual decline exhibit the most extensive alterations in metabolic profiling of lysoPCs, ceramides, IDO activity, and homoarginine synthesis. Alterations in these metabolites may indicate mitochondrial dysfunction, compromised immunity, and elevated burden of cardiovascular and kidney pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.